Partial inhibition of TYK2 mitigates tau pathologies in cells and mice, highlighting TYK2 as a potential therapeutic target for Alzheimer’s disease and other tauopathies. The gene discussed is TYK2; the disease is early-onset autosomal dominant Alzheimer disease.